Incidence and prevalence of hepatitis B and hepatitis C viruses in hemodialysis patients in Lebanon

Antoine Abou Rached, Lara El Khoury, Talal El Imad, Abdallah S Geara, Josette Jreijiry, Walid Ammar

Antoine Abou Rached, National Hepatitis Program, Ministry of Public Health, Beirut 1106 9800, Lebanon
Antoine Abou Rached, Department of Internal Medicine, Division of Gastroenterology, Lebanese University, Beirut 2903 1308, Lebanon
Lara El Khoury, Talal El Imad, Josette Jreijiry, Faculty of Medical Sciences, Lebanese University, Beirut 2903 1308, Lebanon
Abdallah S Geara, School of Medicine, West Virginia University, Morgantown, WV 26506-9100, United States
Walid Ammar, Ministry of Public Health, Beirut 1106 9800, Lebanon

Author contributions: Abou Rached A was the major investigator who designed the study and contributed to data analysis and paper writing; El Khoury L, El Imad T and Jreijiry J collected the data and contributed to data analysis and paper writing; Geara AS performed the statistical analysis; Ammar W supervised the study and contributed to results analysis.

Institutional review board statement: This study is retrospective, involving anonymous clinical data without affecting the patient’s rights and welfare. These data were obtained directly from the ministry of public health registries in collaboration with its general director. No IRB approval was required.

Informed consent statement: We performed a retrospective study using anonymous patients data collected through the ministry of public health which routinely compiles all HBsAg and HCV serology results from the affiliated HD centers across Lebanon on a monthly basis. Since then, no informed consent was required.

Conflict-of-interest statement: No funding has been received for the conduct of this study. There were no financial or personal interests to be disclosed.

Data sharing statement: All data will be made available alongside the article when published. No additional data are available.

Abstract

AIM: To determine the incidence and the prevalence of hepatitis B and C viral infections in patients on hemodialysis (HD) across Lebanon.

METHODS: We reviewed the data registry at the Lebanese Ministry of Public Health where records of monthly hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) serology are reported from 60 affiliated HD centers across Lebanon. All patients who were on HD or who started HD between October 2010 and July 2012 were included in the study. Patients from seven HD centers were excluded due to inadequate and incomplete results reporting. During the selected
INTRODUCTION

The susceptibility to acquire viral hepatitis during hemodialysis (HD) has several potential underlying reasons related to both the patient and the HD procedure. First, although the rate of blood products transfusions has decreased since the introduction of erythropoietin stimulating agents, HD dependent patients still subjects of recurrent transfusions. Second, HD machines and membranes are shared between different patients which increases the risk of direct blood cross contamination within one HD unit. Vaccination does not offer the same level of protection against HBV transmission in HD patients as in the general population and finally and once exposed to HBV or HCV. End stage renal disease (ESRD) patients are more prone to become chronic carriers compared to the general population[1]. Acquiring an HBV and/or HCV infection has long-term impact on morbidity and mortality of HD patients. It has been suggested that HCV seropositivity is associated with all-cause as well as cardiovascular mortality in HD patients[2]. In addition, HBV and/or HCV infection changes the clinical course and the prognosis after kidney transplantation. In Lebanon, HBV and HCV prevalence in HD patients has not been widely studied previously. The available studies were limited to few dialysis centers and date back to the late 1990’s[3-5]. Reassessing the extent of the problem for both viruses establishes the infection control protocols and the general means to prevent transmission of hepatitis infection in ESRD patients on HD.

The main objective of this study is to determine the incidence and the prevalence of HBV and HCV infections in ESRD patients on HD across Lebanon. The current common practice is that ESRD patients on HD should be screened for HBV and HCV infection before the initiation of HD and monitored monthly thereafter. This serology is reported to the ministry of public health (MOPH) on a monthly basis. Our goal is that by establishing the annual incidence of HBV and HCV infection in HD patients in the different centers in Lebanon, we will be able to document how extensive is the viral hepatitis in the Lebanese HD centers. In addition, a secondary objective is to compare the incidence and the prevalence between the different Lebanese regions in order to localize a potentially high risk center.

MATERIALS AND METHODS

Each dialysis center in Lebanon is required to report monthly serology for both HBV (HBsAg) and HCV (HCV antibody) for all its HD patients.

We reviewed the MOPH registry, which compiles all Lebanese dialysis centers data, for the period extending from October 2010 to July 2012. Using this data; we conducted an assessment of the prevalence and incidence of HBV and HCV in the HD population in Lebanon.

The study population included all the patients’ who
underwent HD during the period extending from October 2010 to July 2012 (i.e., both already established ESRD and newly diagnosed ESRD initiated on HD). We only excluded dialysis units and patients who had incomplete, or did not report data for part or for the whole studied period (7 HD centers from a total of 60 HD centers).

**Incidence analysis**

Since we had monthly serology and the patients were starting or stopping dialysis at different date during the studied period, we calculated the incidence using a patient-month (p-m) unit. Each HD patient was represented in the incidence analysis by the total number of months spent undergoing HD (i.e., if a patient was on dialysis only for 10 mo he will be counted in the analysis as 10 p-m).

In the incidence analysis, we excluded all the patients with positive serology at the start of the studied period. For the patients who did not seroconvert during the period they were receiving HD, we counted the total months during which the patient was on HD. For patients who eventually acquired hepatitis viral infection, we only counted the total months before the acquiring infection (the period during which the patient was at risk of acquiring an infection).

Incidence (per patient-month) = (Total number of acquired infection)/(Total patient-month)

At the end of the incidence calculation, we converted the unit p-m to patient-year (p-y) by dividing the final number by 12.

Incidence (per patient-year) = ([Total number of acquired infection]/(Total patient-month))/12

We did the statistical analysis separately for HBV and HCV.

To compare the incidence between the different governorates and since the population is independent, we used a Z-test to compare head to head the incidence of acquiring hepatitis viral infection between the different Governorates. We used a $P < 0.05$ with a two-tailed Z-test to reject the null hypothesis with a 95 percent certainty. Since our sample size was large, our analysis did fulfill the requirement of a study power more than 80%.

**Prevalence analysis**

We divided the total number of patient with positive serology for HBV and HCV separately by the total number of patients studied in this period of time.

\[
\text{Prevalence} = \frac{(\text{Total number of patients with positive serology})}{(\text{Total number of patients})}
\]

There are a total of 60 HD centers in Lebanon, fifty three (88.3%) had a complete data reporting and were included in the analysis. To evaluate the geographic differences in viral hepatitis in Lebanon, each dialysis unit was allocated to a Governorate based on its geographic location. Table 1 layout the geographic distribution of the HD units across Lebanon. The centers with missing data and not included in the analysis were 3 of 27 (11%) of the Governorate of Mount Lebanon (Haroun Hospital; Siblin Governmental Hospital and Serhal Hospital), 2 of 7 (28%) in the Bekaa (Hermel Governmental Hospital, Hraoui Governmental Hospital), 1 of 6 (16%) in South (Hammad Hospital) and 1 of 3 (33%) in Nabatieh (Nabatieh Governmental Hospital).

**RESULTS**

Sixty out of 3769 HD patients studied during a 22-mo period from October 2010 to July 2012 were found to have positive HBsAg and 177 out of 3769 were positive for HCV Antibodies during anytime for this period.

The prevalence of HBV and HCV in HD patients across Lebanon was 1.6% and 4.7%, respectively.

The prevalence of HBV in HD units by governorate was distributed as follows: 1.43% for Beirut, 1.16% for Mount Lebanon, 2.28% for Bekaa, 1.47% for the South, 2.37% for the North and 1.13% for Nabatieh. The prevalence of HCV by Governorate was distributed as follows: 3.57% for Beirut, 4.47% for Mount Lebanon, 5.58% for Bekaa, 7.07% for the South, 5.01% for the North and 0% for Nabatieh. We did not analyze the difference in the prevalence between each Governorate since it is difficult to interpret such results due to the frequent shift of patient between dialysis units (i.e., some patients switch HD center between seasons and relocate to Mount Lebanon or Beirut during the winter season). The geographical distribution is detailed in Tables 2 and 3.

The incidence of HBV in HD centers in Lebanon was 0.27 per 100 p-y, while for HCV it was 0.37 per 100 p-y (Table 4). No newly acquired infection for both HBV and

---

### Table 1 Distribution of hemodialysis centers across Lebanon

| Governorates | No. of centers present | No. of centers with available data | No. of patients studied during this period |
|--------------|------------------------|-----------------------------------|------------------------------------------|
| Beirut       | 6                      | 6                                 | 559                                      |
| Mount Lebanon| 27                     | 24                                | 1632                                     |
| Bekaa        | 7                      | 5                                 | 394                                      |
| South        | 6                      | 5                                 | 339                                      |
| North        | 11                     | 11                                | 757                                      |
| Nabatieh     | 3                      | 2                                 | 88                                       |
| Total        | 60                     | 53                                | 3769                                     |

### Table 2 Calculated total patient months for hepatitis B

| Governorates | Total number of patients | Total patient-month | Patients with positive HBsAg | Newly acquired hepatitis B |
|--------------|--------------------------|---------------------|-----------------------------|----------------------------|
| Beirut       | 559                      | 7232                | 8                           | 2                          |
| Mount Lebanon| 1632                     | 23955               | 19                          | 3                          |
| Bekaa        | 394                      | 4026                | 9                           | 2                          |
| South        | 339                      | 4379                | 5                           | 1                          |
| North        | 757                      | 13014               | 18                          | 4                          |
| Nabatieh     | 88                       | 1120                | 1                           | 0                          |
| Total        | 3769                     | 53726               | 60                          | 12                         |

HBsAg: Hepatitis B surface antigen.
HCV were observed in Nabatieh.

While comparing the incidence of HBV in HD units between different governorates in Lebanon, no statistically significant difference was found (with a P-value always higher than 0.05) (Table 5). In Contrast, a statistically significant difference was found between the incidence of HCV in the South (1.47 per 100 p-y) compared to Mount Lebanon (0.21 per 100 p-y) and the North (0.19 per 100 p-y) showing a higher incidence in the South with a P-value of 0.00068 and 0.00374 respectively (Tables 5 and 6 for a list of the different calculated P-values).

**DISCUSSION**

It is well known that HD patients are at high risk for HCV and HBV infections. In Lebanon three small studies were done concerning the prevalence of HCV in HD patients. Naman et al reported in 1996 that the prevalence of HCV among HD in Lebanon was 27% with a high variation between the 5 centers studied (10%-39%), Abdelnour et al reported in 1997 in various hospitals a prevalence of 16%, Abourached et al reported in 2006, a prevalence of 13% (2.2%-38%) in 17 HD centers in Lebanon.

In this epidemiologic study covering more than 88% of the HD centers in Lebanon, the prevalence of anti-HCV antibodies in ESRD patients undergoing HD was 4.7%, showing a decrease in the prevalence of HCV among HD patients in Lebanon over the last two decades. The lowest prevalence was in Beirut (3.5%) and the highest in the South (7%). We observed a high variability among the 53 different centers studied, ranging from as low as 0% to as high as 20%.

The reduction in HCV prevalence in HD patients is a common trend across several countries and it was mainly related to the reduction in the number of transfusions in HD patients and the improvement of the laboratory screening techniques for detection of anti-HCV antibodies in blood donors. The prevalence of HCV infection in patients on HD is highly variable but clearly much higher than in the general population of the respective countries. In phase one of the Dialysis Outcomes and Practice Patterns Study (DOPPS), a prospective observational study of adult HD patients randomly selected from 308 representative dialysis facilities in France, Germany, Italy, Japan, Spain, the United Kingdom, and United States, an overall HCV prevalence of 13% was found in 8615 patients.[15]

Globally the prevalence of HCV among patients undergoing HD varies from as low as 6.1% in Germany in 2002[16] to as high as 76% in Casablanca in 2005[8]. In general, North Africa and the Middle East were cited as high prevalence areas, both in the general population and in HD patients, by the WHO in 1999[17]. Previous studies from the region have reported a prevalence of anti-HCV antibodies in HD patients of 50% in Saudi Arabia in 2000[10], 19.1% in Tunisia in 1994[11], 20.2% in Turkey in 2006[12] and 34.6% in Jordan in 2007[13].

Concerning the prevalence of HBV, Abourached et al reported on 2007 a prevalence of 2.62% (0%-6.5%) of HBsAg in 17 HD centers in Lebanon, our study showed a decrease of the prevalence to 1.6%, ranging from 1.4% in Nabatieh and Bekaa, to 2.4% in the North. This prevalence is slightly elevated than that reported in different study In Lebanon concerning the general population[14]. We observed a high variability among the 53 different centers, ranging from as low as 0% to as high as 15%. This observed prevalence is lower than that reported in the 2008 by the Saudi Centre for Organ Transplantation (SCOT) report, where HBV seropositivity was 4.6% in the Saudi HD population while among Jordanian HD patients it was 5.9%.[15]. It is also lower than that reported in HD patients in other regions including Europe (4.1%), Japan (2.2%) and the United States (2.4%) during the period extending from 1996 to 2002[16]. A study sample from the DOPPS, which included 8615 adult HD patients from 308 dialysis facilities in Western Europe and the United States, reported prevalence rates for HBV infection ranging from 0% to 6.6%[17]. Studies from less developed countries estimated that the proportion of HBsAg carriers in the HD population varies from 2% to 20%.[18,19].

Prospective follow up of seronegative HD patients enabled us to observe 12 newly acquired infection for HBV and 16 newly acquired infection for HCV during a twenty two month period. We observed a 0.37 per 100 p-y incidence of new HCV infections during the 22-mo observation period. The reported incidence of new HCV infections varies considerably between countries. A rate

---

**Table 3** Total patient-months distribution for hepatitis C

| Governorates   | Total number of patients | Total patient-months | Patients with positive HCV Abs | Newly acquired hepatitis C |
|---------------|-------------------------|----------------------|-------------------------------|----------------------------|
| Beirut        | 559                     | 7035                 | 20                            | 3                          |
| Mount Lebanon | 1632                    | 22970                | 73                            | 4                          |
| Bekaa         | 394                     | 3797                 | 24                            | 2                          |
| South         | 339                     | 4078                 | 24                            | 5                          |
| North         | 757                     | 12997                | 38                            | 2                          |
| Nabatieh      | 88                      | 1142                 | 0                             | 0                          |
| Total         | 3769                    | 51639                | 177                           | 16                         |

HCV: Hepatitis C virus.

**Table 4** Incidence of hepatitis B and hepatitis C among hemodialysis centers in Lebanon

| Governorates   | Incidence of HBV (per 100 p-y) | Incidence of HCV (per 100 p-y) |
|---------------|--------------------------------|--------------------------------|
| Beirut        | 0.33                           | 0.51                           |
| Mount Lebanon | 0.15                           | 0.21                           |
| Bekaa         | 0.59                           | 0.63                           |
| South         | 0.27                           | 1.47                           |
| North         | 0.37                           | 0.19                           |
| Nabatieh      | 0                              | 0                              |
| Across Lebanon| 0.27                           | 0.37                           |

HCV: Hepatitis C virus; HBV: Hepatitis B virus.
as low as 0.4% was observed in France from 1997 to 2000\cite{20} but higher rates have been reported from the Mediterranean region. According to the 2008 SCOT report, the annual rate of HCV sero-conversion in Saudi HD patients was 7%-9% while in Jordan it was 2.6%\cite{14}.

The incidence rate of 0.27 per 100 p-y for HBsAg is slightly less than that reported in Europe, Japan and the United States (0.4-1.8 per 100 p-y)\cite{17}. While comparing the incidence of HBV infection among the different Governorates, no statistically significant difference was found. In contrast, a statistically significant difference in the incidence of HCV infection was found between the South and both Mount Lebanon and the North. This interestingly high incidence of HCV infection of 1.47 per 100 p-y found in the South need to be assessed further to be able to find a potential reason for this higher incidence.

In this study we collected data from 53 centers distributed across all the six Governorates of Lebanon from the total 60 centers reporting monthly serology to the MOPH, giving us a total of 3769 patients studied over a 22-mo period. This significantly increased the statistical power and the validity of the results.

In general, the prevalence and incidence of HBV and HCV infections in HD patients are directly related to the prevalence of these infections in the general population, the quality of healthcare services in a community and the standards of infection control practices in HD units. In Lebanon, patients on maintenance HD were found to have a higher prevalence of HCV infection of 4.7% when compared to the general population since, according to available data, anti-HCV prevalence rate of 0.2% to 0.4% of the general population in Lebanon\cite{21}, but we noted a significant decrease of this prevalence in this group of patients during the last 20 years. Also the prevalence of HBV was slightly higher than the general population 2.62% vs 2.2%.

This higher prevalence of HBV and HCV infection in HD compared to the general population has been confirmed by several reports from different countries\cite{22}.

The incidence of HBV and HCV in HD centers in Lebanon is very low compared to others countries in the region, this can be due to the good applications of the standards of infection control practices in HD centers and the strict surveillance by the MOPH.

A notable result of this study was the significantly higher incidence of HCV found mainly in the South that may be due to variation in the degree of implementation of the universal precautions to prevent nosocomial transmission. In order to evaluate the reason for the variation between the different HD units, a more detailed evaluation of each dialysis patient should be done especially in the units with the lowest and the highest incidence for HBV or HCV. Such studies would assist in

\begin{table}
\centering
\caption{P-values for hepatitis B}
\begin{tabular}{llllll}
\hline
HBV & Beirut & Mount Lebanon & Bekaa & South & North & Nabatieh \\
\hline
Beirut & $P = 0.3759$ & $P = 0.5562$ & $P = 0.8702$ & $P = 0.8948$ & $P = 0.579$ \\
& NS & NS & NS & NS & NS \\
Mount Lebanon & $P = 0.1059$ & $P = 0.6073$ & $P = 0.2208$ & $P = 0.7086$ \\
& NS & NS & NS & NS & NS \\
Bekaa & $P = 0.5038$ & $P = 0.5709$ & $P = 0.4578$ \\
& NS & NS & NS & NS & NS \\
South & $P = 0.778$ & $P = 0.6159$ \\
& NS & NS & NS & NS & NS \\
North & $P = 0.5547$ \\
& NS & NS & NS & NS & NS \\
Nabatieh & \\
& NS & NS & NS & NS & NS \\
\hline
\end{tabular}
\end{table}

\begin{table}
\centering
\caption{P-values for hepatitis C}
\begin{tabular}{llllll}
\hline
HCV & Beirut & Mount Lebanon & Bekaa & South & North & Nabatieh \\
\hline
Beirut & $P = 0.229$ & $P = 0.8164$ & $P = 0.1274$ & $P = 0.2598$ & $P = 0.4854$ \\
& NS & NS & NS & NS & NS \\
Mount Lebanon & $P = 0.1822$ & $P = 0.00068$ & $P = 0.9079$ & $P = 0.6548$ \\
& NS & NS & NS & NS & NS \\
Bekaa & $P = 0.2951$ & $P = 0.2036$ & $P = 0.438$ \\
& NS & NS & NS & NS & NS \\
South & $P = 0.00374$ & $P = 0.2346$ \\
& NS & NS & NS & NS & NS \\
North & $P = 0.6707$ \\
& NS & NS & NS & NS & NS \\
Nabatieh & \\
& NS & NS & NS & NS & NS \\
\hline
\end{tabular}
\end{table}

NS: Non-significant; HBV: Hepatitis B virus.

NS: Nonsignificant; HCV: Hepatitis C virus.

Abou Rached A et al. Hepatitis B and C in hemodialysis patients in Lebanon
guiding interventions aiming to reduce the occurrence of these infections and thus reduce the morbidity and mortality of the HD population in Lebanon. Finally this study demonstrated a reduce in the prevalence of HBV and HCV infections in HD centers during the last 2 decades and a low incidence rate due to the good applications of the standards of infection control practice.

COMMENTS

Background
End stage renal disease (ESRD) patients on hemodialysis (HD) are particularly at higher risk for acquiring hepatitis C virus (HCV) and hepatitis B virus (HBV) than the general population, due to the sharing of contaminated machines within the same center and the higher rates of blood transfusions. Such infections have a negative impact on the clinical course of ESRD causing higher rates of morbidity and mortality. Since then, it is essential to determine the prevalence and the incidence of HBV and HCV infections in HD patients in each country, then to decide accordingly about further interventions to control such infections.

Research frontiers
The prevalence of HCV and HBV in patients on HD in Lebanon was only addressed by small studies including few HD centers. This study will determine the prevalence and incidence of HBV and HCV in a significantly larger population including 3769 HD patients through 88% of all HD centers across Lebanon between October 2010 and July 2012.

Innovations and breakthroughs
Previous studies done on smaller sample sizes limited to some Lebanese HD centers reported a prevalence of 2.6% and 13%-27%, for HBV and HCV, respectively. No reports are yet available about their incidence rate. Although accurate comparison could not be done due to the different sample sizes, this study showed a reduction in HBV and HCV prevalence through HD patients in Lebanon (1.6% and 4.7%, respectively). On the other hand, their calculated prevalence and incidence rates were found to be among the lowest values reported in other countries, either in the Middle East, or in Europe and United States. Another notable result of this study was the significantly higher incidence rate of HCV in the Southern Lebanese HD centers.

Applications
This study reflects an appropriate adherence to standards of infection control in the Lebanese HD centers limiting the spread of HBV and HCV between HD patients. However, it emphasizes the need for further investigations to reestablish those standards in some centers having significantly higher incidence rate of HCV, located mainly in the South of Lebanon.

Peer-review
In this manuscript, the authors report on the prevalence and incidence of hepatitis B and hepatitis C among HD patients in Lebanon. This paper is clinically interesting.

REFERENCES

1 Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of hepatitis B surface antigenemia (HBs Ag) in hemodialysis patients. Arch Intern Med 1979; 139: 178-180 [PMID: 434972 DOI: 10.1001/archinte.1979.03630390036015]
2 Kato A, Takita T, Furushashi M, Fujimoto T, Suzuki H, Maruyama Y, Sako Y, Miyajima H. Association of HCV core antigen seropositivity with long-term mortality in patients on regular hemodialysis. Nephron Extra 2012; 2: 76-86 [PMID: 22619670 DOI: 10.1159/000337333]
3 Abdelnour GE, Matar GM, Sharara HM, Abdelnour AM. Detection of anti-hepatitis C virus antibodies and hepatitis C virus RNA in Lebanese hemodialysis patients. Eur J Epidemiol 1997; 13: 863-867 [PMID: 9476813 DOI: 10.1023/A:1001337039040]
4 Naman RE, Mansour I, Klayne S, Khalil G. [Hepatitis C virus in hemodialysis patients and blood donors in Lebanon]. J Med Liban 1996; 44: 4-9 [PMID: 8963518]
5 Abourached A, Saniori P, Bou Jaoude J. Prevalence des hepatites B et C chez les donneurs de sang, les hemodialyses et les toxico-manes au Liban. Available from: URL: http://www.snfge.org/content/P12. 2007
6 Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three countries: the DOPPS. Kidney Int 2004; 65: 2335-2342 [PMID: 15149347 DOI: 10.1111/j.1523-1755. 2004.00649.x]
7 Hinrichsen H, Leinenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-433 [PMID: 12171969 DOI: 10.1136/gut.51.3.429]
8 Boulouajjaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D, Benchemsi N. [Prevalence of hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-Rochd university hospital, Casablanca]. Nephrol Ther 2005; 1: 274-284 [PMID: 16895696 DOI: 10.1016/j.nephro.2005.06.012]
9 Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47 [PMID: 10847128 DOI: 10.1046/j.1365-2893.1999.6120139.x]
10 Souqiyss MZ, Al-Attar MB, Zakaria H, Shaheen FA. Dialysis centers in the kingdom of saudi arabia. Saudi J Kidney Dis Transpl 2001; 12: 293-304 [PMID: 18209376]
11 Jemni S, Ikbel K, Kortas M, Mahjoub J, Ghachem L, Bidet JM, Boukef K. Seropositivity to hepatitis C virus in Tunisian haemodialysis patients. Nouv Rev Fr Hematol 1994; 36: 349-351 [PMID: 7534398]
12 Yakaryilmaz F, Gurubz OA, Gulerit S, Mert A, Songur Y, Karakan T, Keles H. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006; 28: 729-735 [PMID: 17162434 DOI: 10.1080/0886020062000925602]
13 Nabuusi MM, El Saleeby CM, Araj GF. The current status of hepatitis B in Lebanon. J Med Liban 2003; 51: 64-70 [PMID: 15298159]
14 Batieha A, Abdallah S, Maghaireh M, Awad Z, Al-Akash N, Batiench A, Ajlouni KA. Epidemiology and cost of haemodialysis in Jordan. East Mediterr Health J 2007; 13: 654-663 [PMID: 17687839]
15 Al Hijazat M, Ajlouni YM. Hepatitis B infection among patients receiving chronic hemodialysis at the Royal Medical Services in Jordan. Saudi J Kidney Dis Transpl 2008; 19: 260-267 [PMID: 18310881]
16 Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44: 16-21 [PMID: 15486869 DOI: 10.1016/S0272-6386(04)01100-X]
17 Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Karokowa K, Combe C, Saito A, Labrecque J, Port FK, Young EW. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003; 63: 2222-2229 [PMID: 12753311 DOI: 10.1111/j.1523-1755.2003.00117.x]
18 Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, Yoshida CF, Martins RM. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz 2006; 101: 689-692 [PMID: 17072485 DOI: 10.1590/S0074-027620060000060019]
19 Telaku S, Fejza H, Elezi Y, Bicaj T. Hepatitis B and C in dialysis units in Kosovo. Viroj J 2009; 6: 72 [PMID: 19497116 DOI: 10.1186/1743-422X-6-72]
20 Izopet J, Sandres-Sauné K, Kamar N, Salama G, Dubois M,
Pasquier C, Rostaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. *J Med Virol* 2005; 77: 70-76 [PMID: 16032714 DOI: 10.1002/jmv.20415]

21 Araj GF, Kfoury-Baz EE, Barada KA, Nassif RE, Alami SY. Hepatitis C virus: prevalence in Lebanese blood donors and brief overview of the disease. *J Med Liban* 1995; 43: 11-16 [PMID: 8676356]

22 Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. *Hepatology* 2002; 36: 3-10 [PMID: 12085342 DOI: 10.1053/jhep.2002.34613]
